The Motley Fool··Eric VolkmanKinikska Pharma Surges 24% on Strong Q1 Beat and Arcalyst Guidance Hike
Kinikska Pharmaceuticals surged 24% after Q1 earnings beat. Arcalyst revenue jumped to $214M; net income more than doubled. Company raised full-year Arcalyst guidance to $930-945M.
KNSAbiotechrevenue growth